Company Overview: Immutep Limited (ASX: IMM) is an Australia-based clinical-stage biotechnology company focused on developing innovative immunotherapy treatments for cancer and autoimmune diseases. The company specialises in therapies targeting the Lymphocyte Activation Gene-3 (LAG-3) immune control pathway, which plays a key role in regulating the body’s immune response. This Report covers the Price Action, Technical Indicators Analysis along with the Support Levels, Resistance Levels, and Recommendations on this stock.
On the daily chart, IMM continues to trade below a key horizontal resistance zone, highlighting ongoing weakness in near-term price action and suggesting that upside momentum remains limited. Momentum indicators remain…
